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1 Introduction
The National Institutes of Health (NIH)[1] is an 
agency of the Department of Health and Human 
Services of the US. The mission of the NIH is 
to “expand fundamental knowledge about the 
nature and behavior of living systems and the 
application of that knowledge to extend healthy 
life, and conduct and support research in the 
diagnosis, treatment and prevention of human 
diseases.” The NIH consists of the Office of the 
Director and 27 Institutes and Centers. The Office 
of the Director is responsible for setting policies 
for the NIH and for planning, managing, and 
coordinating the programs and activities of all of 
its institutes and centers. The 27 institutes and 
centers include the National Cancer Institute, 
the National Heart, Lung and Blood Institute, and 
the National Human Genome Research Institute. 
The NIH conducts research through these 
institutes and centers, and fosters research work 
at universities and research institutes both in the 
US and abroad by providing grants and funding 
opportunities.
NIH announced on September 30, 2003 the 
“NIH Roadmap” that outlines its “strategy to 
accelerate biomedical research progress.” The 
NIH Roadmap provides a framework of the 
priorities the NIH must address in order to 
improve its research capabilities and speed the 
movement of research discoveries from the bench 
to the bedside.
This article outlines an overall picture of 
the NIH Roadmap by illustrating its objective, 
crafting process, pressing issues, and other major 
features.
2 NIH R&D Budget
Congress has not yet approved the NIH R&D 
budget bill for FY 2004[2]. The bill, which had 
been passed by the Lower House on December 
8, 2003, is expected to be approved by the Upper 
House in January 2004. If approved, the bill 
would provide the NIH with $27.1 billion in FY 
2004 (up 3.2% from FY 2003). The nation’s R&D 
budget totals $127 billion, of which $56 billion 
are directed to non - defense programs. This 
means that the NIH budget accounts for nearly 
50% of the nation’s non-defense budget[3].
The NIH R&D budget continued to mark a 7 
to 8% annual increase until FY 1998. Upon the 
launch of the “doubling of NIH budget” under 
the initiative of President Clinton in FY 1999, 
the NIH budget continued to mark outstanding 
annual growth of 14 to 15% (see Table 1). The 
NIH budget request for FY 2004, however, shows 
that such a rapid increase has come to an end, as 
it proposes a 3.2% increase from FY 2003[2,4].
The NIH budget doubling campaign effectively 
increased the budget for all NIH institutes. For 
 * Figure for the final NIH budget for FY 2003
 ** Figure for the NIH budget as of December 8, 2003
Source: Author’s compilation based on Reference[2,4].
Fiscal year Budget (million $)
Comparison with 
previous year (%)
    1998 13,110  7.3
    1999 14,995  14.4
    2000 17,234  14.9
    2001 19,807  14.9
    2002 22,714  14.7
    2003* 26,245  15.5
    2004** 27,093  3.2
Table 1 :Change in the NIH R&D Budget [2,4]
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example, “Human Genome Research” saw a 
substantial increase in its R&D budget from FY 
1999 to FY 2000 due to the strengthened effort 
to map the human genome. The Human Genome 
Project made a major breakthrough when the 
human genome was finally sequenced in 2001. 
There has also been a rapid increase in the R&D 
budget for “Allergy and Infectious Diseases” since 
FY 2002[5-9].
3 Background to the Creation
 of the NIH Roadmap
There are two major factors that prompted the 
NIH to chart the priority initiatives entitled the 
“NIH Roadmap.”
Firstly, the NIH intends to continue using 
its research potentials recognized during the 
doubling of NIH budget, which lasted five years 
from FY 1999 to FY 2003. Secondly, Dr. Elias A. 
Zerhouni was appointed the new NIH director in 
May 2002.
4 Overview of
 the “NIH Roadmap”
This chapter outlines the NIH Roadmap based 
on official information on the NIH website[10, 11].
4-1 Purpose
The purpose of the NIH Roadmap was to 
“identi f y major oppor tunit ies and gaps in 
biomedhical research that no single institute at 
NIH could tackle alone but that agency as a whole 
must address to make the biggest impact on the 
progress of medical research.” Traditionally, the 
NIH conducts research through its 27 institutes 
and centers to faci l itate its own research 
programs and offer funding opportunities. The 
NIH Roadmap, however, highlights the “priorities 
the NIH must address by transcending traditional 
departmental boundaries.”
The NIH decided to craft the NIH Roadmap 
due, in par t, to a change in the nature of 
biomedical research. This change was initiated 
by the complet ion of the human genome 
sequence, which dramatically increased the 
speed of new discoveries in the last few years. 
However, the complexity of biology remains a 
daunting challenge for the NIH, which aims at 
transforming scientific knowledge into tangible 
benefits for people. To meet that challenge, 
the NIH had to review its strategy to conduct 
b iomed ica l  resea rch and br i ng  resea rch 
discoveries from the bench to the bedside.
4-2 Crafting Psrocess
Soon af ter becoming the director of the 
National Institutes of Health (NIH) in May 
2002, Dr. Elias A. Zerhouni convened a series 
of meetings and consultations to chart the NIH 
Roadmap. 
The initial step in craf ting the Roadmap 
process involved a ser ies of f ive meetings. 
More than 300 nationally recognized leaders in 
academia, industry, government, and the public 
discussed about the most compelling initiatives 
that the NIH should pursue over the next 10 
years. Participants were asked to address three 
key questions. “What are today’s most pressing 
scientific challenges?,” “What are the roadblocks 
to progress, and what must be done to overcome 
them?,” and “What is the responsibility of the NIH 
as a whole?” Through discussions, three major 
areas (themes) emerged.
Later, a series of Institute Director- chaired 
Working Groups of NIH staff were formed to 
make final selections of key initiatives on the 
advice of the NIH Council and the NIH Advisory 
Committee. 
The NIH leadership weighed all initiatives in 
the context of several broad criteria to make final 
selections that deserve funding. These criteria 
include: “Is the initiative truly transforming - will 
it dramatically change the content or the process 
of medical research in the next decade?,” “Would 
outcomes from the initiative be used by, and 
synergize the work of, many institutes?,” “Will 
the initiative be compelling to NIH stakeholders, 
especially the public?,” and “Does the initiative 
position the NIH to do something that no other 
entity can or will do?”
The Roadmap working groups were then 
grouped into several Implementation Groups 
to devise and examine detailed implementation 
plans, and short- and long-term objectives for the 
next stage of the Roadmap for FY 2004.
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4-3 Major NIH Roadmap Areas Themes
(1) New Pathways to Discovery
This theme addresses the need “to understand 
complex biological systems.” Having completed 
the sequencing of the human genome, further 
progress in medicine will require quantitative 
knowledge about the many interconnected 
networks of molecules that comprise cells and 
tissues, along with improved insights into how 
these networks are regulated and interact with 
each other. Implementing groups in this area will 
address several initiatives, including “Structural 
Biology,” “Proteomics (research to determine the 
amounts, locations, and interactions of the large 
numbers of individual proteins within a single 
cell),” and “Metabolomics (research to determine 
the metabolic components and networks within 
the cell).”
In this set of initiatives, researchers will also 
build a better “toolbox” for today’s biomedical 
research. To ful ly capital ize on the recent 
sequencing of the human genome and many new 
discoveries in molecular and cell biology, these 
initiatives address the research community’s need 
for database access and analytical technologies.
With this theme, the Roadmap addresses the 
following five initiatives.
(i) Building Blocks, Pathways, and Networks
•  The Nat iona l  Technology Centers for 
Networks and Pathways will be established 
to  promote  the  deve lopment  o f  new 
technologies to describe the dynamics of 
protein interactions. The center will also 
develop instruments, methods and reagents 
for quantitat ive measurements and for 
measurements at very short timescales.
•  New technologies will be developed to study 
metabolomics. Knowledge gained from 
these studies will be used to understand the 
role of metabolites in the context of cellular 
pathways and networks.
•  Workshops wi l l  be convened to study 
proteomics and metabolomics in order to 
establish data standards for research in 
proteomics and metabolomics, and investigate 
ways for establishing an evaluation index for 
future research in proteomics.
(ii) Molecular Libraries and Molecular Imaging
•  The NIH Bioactive Small Molecule Library and 
the Screening Centers will be established to 
develop new screening methods and provide 
a public molecule library.
•   A  d a t ab a s e  o f  che m ic a l  s t r uc t u r e s ,  
properties, and activities will be established. 
A competitive research fund will also be 
established to promote the development of 
tools and technologies for chemiformatics.
•  Compounds as basic research tools will be 
developed. Bottlenecks in the development of 
compounds as drugs will be targeted.
•  An imaging probe with strong detection 
sensitivity and specificity will be developed. 
A 1,000-fold improvement in imaging probe 
detection sensitivity is targeted, ultimately, 
for basic research and clinical applications. 
The initial step is to achieve a 10 to 100-fold 
improvement within five years.
•  A database of specificities, activities and 
applications of an imaging probe will be 
established.
•  The core faci l ity wil l be established to 
provide imaging proves and generate novel 
imaging probes.
(iii) Structural Biology
•  Methods wil l be developed to produce 
protein samples that scientists can use to 
determine the three-dimensional structure 
of a protein, and apply obtained knowledge 
to determine the structure of membrane 
protein.
(iv) Bioinformatics and Computational Biology
•  The Nat iona l  Centers  for  B iomedica l  
Computing will be developed. This initiative 
wi l l   a l so  create  a  nat iona l  sof t ware  
engineering system in which researchers will 
be able to tap into a supercomputing network 
from anywhere in the country to share and 
analyze data.
(v) Nanomedicine
•  A series of workshops will be convened 
in FY 2004 to prepare for the launch of 
the Nanomedicine Centers in FY 2005. 
These Centers will focus on quantitative 
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measurement of biological processes at the 
nanoscale and the engineering of new tools to 
intervene at the nanoscale. This research will 
help scientists construct miniature pumps for 
drug delivery or tiny sensors to determine the 
cause of a disease.
(2) Research Teams of the Future
This theme is intended to address the issue 
of research system by implementing three 
initiatives: “Introduction of a new funding 
system,” “Interdiscipl inary Research,” and 
“Public-Private Partnerships.”
(i) High-Risk Research
A new f und ing system ( NIH Di rector ’s  
Innovator Awards) will be introduced to provide 
support for “high-risk medical research that may 
achieve a major breakthrough.” Historically, the 
NIH has almost exclusively supported low-risk 
research projects, because more detailed research 
proposals were selected over creative but 
high-risk proposals under its existing peer review 
system. The new award evaluates individual 
scientists in terms of their creative abilities, 
originalities, evidence of focused skillful habits 
of mind that predict perseverance and thorough 
exploration of his/her ideas, and prospects for 
making seminal biomedical research advances. 
In other words, originality or the potential of 
individual scientists weigh more than research 
proposals.
(ii) Interdisciplinary Research
There is a growing need for researchers 
to transcend the tradit ional depar tmental 
boundaries and to work with researchers in other 
areas of scientific interest, as today’s biomedical 
research becomes increasingly diverse and 
complex. For instance, radiologists, physicists, 
biologists, and computer programmers may 
need to work together to solve a problem of 
image analysis. To keep pace with the changing 
nature of biomedical research, these initiatives 
wi l l  encourage researchers to “integrate 
different scientific disciplines.” With this theme, 
the Roadmap seeks to address the following 
initiatives.
•  Grants will be awarded to interdisciplinary 
research programs that use new approaches. 
A total of 15 grants will be awarded in FY 
2004.
•  Training will be provided to scientists in 
interdisciplinary research programs. This 
new model of funding will be introduced in 
FY 2004.
•  Technologies and methods will be developed 
to facilitate interdisciplinary research.
•  Structural barr iers wi l l be removed to 
facilitate interdisciplinary research.
•  A model program for interdiscipl inary 
research wil l be established within the 
NIH to provide training to scientists in 
interdisciplinary research and establish 
an interdisciplinary research team. The 
feasibility and benefits of the program will 
also be examined.
•  The NIH and National Science Foundation 
( NSF )  wi l l  hold the f i r s t  i nteragency 
conference in FY 2004 to discuss “what needs 
to be done to encourage progress in the 
physical science that will provide support and 
underpinning in the future for advances in 
the life sciences.”
(iii) Public-Private Partnerships
“Novel partnerships between the public and 
private sectors” will be encouraged to accelerate 
the movement of scientific discoveries from the 
bench to the bedside. There are two initiatives to 
encourage Public-Private Partnerships.
•  The Public-Private Sector Liaison will serve 
as a resource to NIH staff on partnerships to 
set up an internal Public-Private Partnerships 
Coordinating Committee.
•  Partnership Meetings will provide the NIH 
and potential partner organizations with 
opportunities to meet to discuss potential 
partnerships.
(3) Re-engineering the Clinical Research
 Enterprise
With this theme, the Roadmap addresses the 
need for “Re-engineering the Clinical Research 
Enterprise.”
Ideally, basic research discoveries are quickly 
transformed into diagnostics, drugs, treatments 
or methods for prevention. Such translation lies 
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at the very heart of the NIH’s mission. The NIH 
has succeeded in fulfilling that mission. If such 
efforts are to remain as successful as they have 
been in the past, the NIH must renew its effort to 
improve the health of the people.
In the past, all research for a clinical trail could 
be conducted in one academic center. Clinical 
research, however, has become more difficult 
to conduct over the years. Today, it is necessary 
to develop new partnerships among organized 
pat ient  com mu n it ie s ,  com mu n it y - ba sed  
physicians, and academic researchers in order 
to conduct clinical research. To address such 
need, the NIH will promote the creation of better 
integrated networks of academic centers to speed 
clinical applications of basic research discoveries 
and enhance clinical research capabilities. This 
theme is intended to address this crucial area by 
implementing the following initiatives.
•   A  c l i n ica l  r e s e a rch  proce s s  w i l l  be  
coordinated, standardized and streamlined.
•  The efficiency and productivity of the nation’s 
clinical research enterprise will be enhanced 
through the creation of clinical research 
networks.
•  Specialized training will be offered to clinical 
researchers.
•  The National Electronic Clinical Trials and 
Research Network will be established as the 
standard data system that enables clinical 
researchers to share data and resources.
•  The translation of basic discoveries to early 
phase clinical testing (translational research) 
will be promoted.
•  The Regional Translational Research Centers 
will be established to increase interactions 
between basic and cl in ica l  scient ists.  
The essential core infrastructure will be 
consolidated into these centers.
•  Technologies will be developed to better 
quantify clinically important symptoms and 
outcomes, including pain and fatigue and to 
determine the severities of illnesses. 
5 Conclusion
The NIH plans to set up a common pool of 
resources to facilitate the effort to implement 
the NIH Roadmap initiatives across the NIH 
as a whole. In FY 2004, $130 million will be 
committed to the Roadmap initiatives, with a 
total of $2.1 billion for five years to come[12]. 
This is a new attempt for the NIH, as it has 
always distributed a budget to all of its institutes 
and centers. The NIH will play a central role in 
shaping a budget and observing the progress of 
implementation, with each implementing group 
translating a plan into action on behalf of the NIH 
as a whole.
Present ly, the NIH is invit ing scient ists 
to submit research proposals for obtaining 
competitive research funds on website, which 
are intended to support the NIH Roadmap 
initiatives. The NIH will begin to implement 
most of the initiatives in FY 2004 (from October 
2003 to September 2004). At the beginning of 
FY 2004, applications were being received for 
several Roadmap-related competitive research 
funds. A gradual rise in the number of Roadmap 
related funding opportunities shows that the 
NIH is committed to moving towards a full-scale 
implementation of the Roadmap initiatives.
It is believed that the announcement of the 
NIH Roadmap at the beginning of FY 2004 was 
prompted by the need to present a new policy for 
the NIH as a whole, following the appointment of 
the new NIH director and the completion of the 
doubling of NIH budget in FY 2003.
The “NIH Roadmap” does not set a clear 
milestone for its initiatives. Rather, it lays out 
the direction for future research. In the area 
of basic research, post - genome research, 
development of post-genome analytical tools, 
and interdisciplinary research are made the 
priority initiatives. This shows that the NIH gives 
the utmost priority to the facilitation of clinical 
research in consideration of its mission.
We will watch the future development of 
the NIH Roadmap closely to report on how the 
President’s Budget proposals for FY 2005 weigh 
on the NIH initiatives and how Congress alters 
and agrees the budget for final approval.
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